Saw Palmetto
drugOn this page
Also known as Abal fructusBrahea serrulata fruitChamaerops serrulata fruitCorypha obliqua fruitCorypha repens fruitDiglossophyllum serrulatum fruitSabal palm fruitSabal serrulataSabal serrulata fruitSaw palmetto berrySaw palmetto fruitSaw palmetto wholeSerenoaSerenoa repensSerenoa repens fruitSerenoa repens fruit dry extractSerenoa repens fruit ethanol extractSerenoa repens wholeSerenoa serrulata fruit
Summary
Saw Palmetto (CHEMBL2108769) is a phase-3 clinical-stage unknown; indicated across 2 conditions including benign prostatic hyperplasia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 2 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108769 |
| Name | Saw Palmetto |
| Type | Unknown |
| Max phase | 3 |
Also known as: Abal fructus, Brahea serrulata fruit, Chamaerops serrulata fruit, Corypha obliqua fruit, Corypha repens fruit, Diglossophyllum serrulatum fruit, Sabal palm fruit, Sabal serrulata, Sabal serrulata fruit, Saw palmetto, Saw palmetto berry, Saw palmetto fruit
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| benign prostatic hyperplasia | 3 | MONDO:0010811 | EFO:0000284 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00037154 | PHASE3 | COMPLETED | Saw Palmetto Extract in Benign Prostatic Hyperplasia |
| NCT01585246 | PHASE1/PHASE2 | COMPLETED | Saw Palmetto: Symptom Management for Men During Radiation Therapy |
| NCT00497939 | Not specified | UNKNOWN | The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: benign prostatic hyperplasia